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Abstract: Levoﬂ  oxacin is a widely used ﬂ  uoroquinolone approved for the treatment of 
complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the 
medical literature identiﬁ  ed ﬁ  ve publications evaluating levoﬂ  oxacin for the treatment of either 
complicated urinary tract infections or acute pyelonephritis. All trials, although variable in 
their inclusion criteria and levoﬂ  oxacin dosing strategies, reported microbiologic, clinical, and 
safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, 
were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. 
Data on levoﬂ  oxacin resistance, both at baseline and after therapy, were limited. Clinical success 
was observed to range from 82.6% to 93% when measured after the completion of therapy. 
These clinical and microbiologic results were comparable to the ﬂ  uoroquinolone comparators 
in all trials. Insufﬁ  cient data are available to evaluate the outcomes in any meaningful patient 
subgroups, including catheterized patients, and those with other speciﬁ  c complicating factors. 
Levoﬂ  oxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and 
dizziness being the most commonly reported adverse events. The published data support the use 
of levoﬂ  oxacin in complicated urinary tract infections and acute pyelonephritis. Further trials 
are necessary to evaluate levoﬂ  oxacin within speciﬁ  c patient sub-populations.
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Introduction
Urinary tract infections are one of the most frequently occurring bacterial infections. In 
the United States alone, they account for over 7 million ofﬁ  ce visits and approximately 
15% of community-prescribed antibiotics (Mazzulli 2001; Foxman 2002). While the 
majority of these infections are uncomplicated, patients with complicated urinary tract 
infections (cUTI) are, by deﬁ  nition, at greater risk for adverse outcomes. Levoﬂ  oxacin, 
a widely-used ﬂ  uoroquinolone, was approved in the US for the treatment of cUTI and 
acute pyelonephritis (AP) in 1996 and, more recently, in 2008 a higher dose, short-course 
regimen was also approved for this indication. This review will examine the clinical data 
available to evaluate the efﬁ  cacy and safety of this antimicrobial for cUTI and AP.
Complicated urinary tract infections and pyelonephritis
Generally, a cUTI is considered to be an infection that occurs in the setting of any 
factor that predisposes to treatment failure or recurrence (McCue 1999). However, no 
true consensus has been reached within the medical community as to what speciﬁ  cally 
deﬁ  nes a cUTI. Traditionally, urinary tract infections in patient populations such as those 
with diabetes mellitus, pregnant females, and males have been considered to be com-
plicated infections (Anderson 1996). Other descriptions of a cUTI have also included 
patients who are elderly, have experienced recent instrumentation or antimicrobial 
treatment, or possess functional or anatomic abnormalities of the genitourinary tract 
(Hooton and Stamm 1991). Ronald et al proposed an alternate classiﬁ  cation scheme, Therapeutics and Clinical Risk Management 2008:4(5) 844
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in which a cUTI is characterized by the presence of structural 
abnormalities (urinary obstructions, neurogenic bladder, etc.), 
metabolic and/or hormonal abnormalities (diabetes mellitus, 
pregnancy, renal impairment, etc.), impaired host responses 
(transplant recipients, neutropenic patients, etc.), or infec-
tion with an unusual pathogen (including yeasts, fungi, and 
antimicrobial-resistant bacteria) (Ronald and Harding 1997). 
Mandell’s Principles and Practice of Infectious Diseases 
deﬁ  nes cUTIs as urinary tract infections in men, pregnant 
women, children, hospitalized patients, and patients with 
functional or structural abnormalities of the urinary tract 
(Sobel and Kaye 2005).
AP is commonly described as an infection of the upper 
urinary tract that encompasses fever and ﬂ  ank pain and/or 
tenderness that are accompanied by dysuria and urinary 
urgency and frequency, although it is more accurately 
diagnosed based on the presence of these symptoms along 
with bacteriuria and acute renal infection (Sobel and Kaye 
2005). AP was formerly treated largely on an inpatient basis, 
but a recent trend towards outpatient management of this 
condition has been noted (Czaja et al 2007). As seen in cUTI, 
the most common pathogen causing AP is Escherichia coli 
(Nicolle 1997; Czaja et al 2007).
The role of ﬂ  uoroquinolones 
in the management of genitourinary 
infections
Currently available ﬂ  uoroquinolones that are approved by the 
US Food and Drug Administration (FDA) for the treatment 
of cUTI and/or AP include ciproﬂ  oxacin, levoﬂ  oxacin, nor-
ﬂ  oxacin, and oﬂ  oxacin. The ﬂ  uoroquinolones gemiﬂ  oxacin 
and moxiﬂ  oxacin are not approved for either condition. 
Gatiﬂ  oxacin was awarded FDA approval for the manage-
ment of cUTI and AP, but this agent was withdrawn from 
the US market in 2006. Levoﬂ  oxacin, approved by the US 
FDA in 1996, is the S enantiomer of the racemate oﬂ  oxacin. 
The S enantiomer of oﬂ  oxacin displays antibacterial activity 
that is approximately 2 orders of magnitude greater than that 
of the R enantiomer; this enhanced activity is due to greater 
binding to and saturation of the binding site on the DNA 
gyrase enzyme (Morrissey et al 1996). Studies of oﬂ  oxacin 
were not included in the present analysis.
The Infectious Diseases Society of America (IDSA) has 
published guidelines for the management of acute uncompli-
cated cystitis and AP (Warren et al 1999). For cases of AP that 
are manageable on an outpatient basis using oral antimicrobial 
therapy, the IDSA recommends a ﬂ  uoroquinolone as the 
preferred empiric therapy, with trimethoprim/sulfamethoxazole 
(TMP/SMX) offered as an alternative. In patients that are to be 
hospitalized, the guidelines recommend the use of intravenous 
therapy with a ﬂ  uoroquinolone, an aminoglycoside with or 
without ampicillin, or an extended-spectrum penicillin with 
or without an aminoglycoside. After such patients are stabi-
lized, the IDSA recommends that the course of treatment be 
completed with an oral ﬂ  uoroquinolone or oral  TMP/SMX. 
Alternatives are recommended for each of the above patient 
populations if the infecting organism is known to be a Gram-
positive coccus. Recommended ﬁ  rst-line agents for the treat-
ment of uncomplicated cystitis include a ﬂ  uoroquinolone 
or TMP/SMX, depending on the local rate of TMP/SMX 
resistance in E. coli. IDSA is currently working towards assem-
bling guidelines for the treatment of cUTI, and publication is 
anticipated in late 2008. The European Association of Urology 
(EAU) has published guidelines that include recommenda-
tions for cUTI, which advise the use of ﬂ  uoroquinolones with 
mainly renal excretion when empiric therapy is necessary. The 
EAU recommends avoiding TMP/SMX as ﬁ  rst-line treatment 
because of the increasingly high prevalence of resistance to 
that antimicrobial agent (Grabe et al 2008).
Fluoroquinolone resistance
Fluoroquinolones have been extensively used in the 
management of genitourinary infections, especially acute 
uncomplicated cystitis. While ﬂ  uoroquinolone resistance in 
uropathogens was once rare, resistance in E. coli has emerged 
and continues to increase. Fluoroquinolone resistance occurs 
through multiple mechanisms including chromosomal 
point mutations in the genes encoding DNA gyrase and/or 
topoisomerase iv, mutations that cause decreased expression 
of outer membrane proteins (OMPs), alterations in the 
lipopolysaccharide (LPS) component of the cell envelope, 
and enhanced ﬂ  uoroquinolone efﬂ  ux by efﬂ  ux pumps such as 
AcrAB (Chenia et al 2006; Chang et al 2007). Plasmid-borne 
resistance has also recently been discovered, and is caused by 
protection of DNA gyrase and topoisomerase IV by Qnr-like 
proteins, including QnrA (Chenia et al 2006). Surveillance 
of urinary isolates collected between 1989 and 1997 found 
that ﬂ  uoroquinolone resistance in E. coli was essentially 
nonexistent during this time frame (Gupta et al 1999a; Gupta 
et al 1999b). More recently, results of the North American 
Urinary Tract Infection Collaborative Alliance (NAUTICA) 
study, a multicenter surveillance study performed between 
2003 and 2004 in the US and Canada, reported that overall 
resistance rates to ciproﬂ  oxacin and levoﬂ  oxacin were 5.5% 
and 5.1%, respectively (Zhanel et al 2006). Similar increases Therapeutics and Clinical Risk Management 2008:4(5) 845
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in ﬂ  uoroquinolone resistance have been noted in the setting of 
AP (Czaja et al 2007). Also, among the emerging extended-
spectrum beta-lactamase (ESBL)-producing E. coli, higher 
rates of ﬂ  uoroquinolone resistance have been reported. In 
China, levofloxacin resistance among ESBL-producing 
E. coli was reported in 86% of isolates (Xiong et al 2002). 
In the US, one healthcare system reported that 56% of 
ESBL-producing E. coli and Klebsiella pneumoniae were 
resistant to ﬂ  uoroquinolones (Lautenbach et al 2001).
Levoﬂ  oxacin pharmacology
Levofloxacin possesses activity against a variety of 
uropathogens, including E. coli (Davis and Bryson 1994). 
The pharmacokinetics of levoﬂ  oxacin have been reviewed 
elsewhere, and a comprehensive evaluation of levoﬂ  oxacin’s 
pharmacokinetics is beyond the scope of this review (Fish 
and Chow 1997). The bioavailability of levoﬂ  oxacin is 100%, 
although absorption is delayed in the presence of food; the 
degree of protein binding ranges from 24 to 38%. Levoﬂ  oxacin 
displays linear pharmacokinetics, and an elimination half-life 
of  7.6 hours after multiple doses of  500 mg. The primary route 
of elimination is renal, with approximately 71% of a dose elim-
inated as unchanged drug within 24 hours. Tissue distribution 
is extensive; urinary levoﬂ  oxacin concentrations have been 
reported to be as high as 128–343 mg/L (the corresponding 
plasma maximum concentration (Cmax) after a single 500 mg 
dose ranges from 4.5 to 5.2 mg/L) (Langtry and Lamb 1998). 
Levoﬂ  oxacin also attains adequate penetration into the prostate, 
with a mean 2.96:1 prostate: plasma concentration ratio, and 
this agent has demonstrated success in the management of 
chronic bacterial prostatitis, including equivalent efﬁ  cacy to 
ciproﬂ  oxacin (Drusano et al 2000; Bundrick et al 2003; Naber 
et al 2008). The urinary excretion of levoﬂ  oxacin (84%) is 
higher than that of ciproﬂ  oxacin (43%), gatiﬂ  oxacin (80%), 
gemiﬂ  oxacin (28%), and moxiﬂ  oxacin (20%) (Naber 2001). 
Renal clearance of levoﬂ  oxacin (but not the plasma Cmax) is 
reduced in the presence of renal impairment.
Few current guidelines describing the optimal treatment 
of cUTI and AP are available, and the role of levoﬂ  oxacin 
in comparison to alternate antimicrobials (including other 
ﬂ  uoroquinolones) in the management of these conditions 
must be further deﬁ  ned. The objective of this review is to 
provide a summary of the clinical efﬁ  cacy and safety of 
levoﬂ  oxacin in the treatment of cUTI and AP.
Methods
The PubMed search engine was used to query the National 
Library of Medicine database using the following search 
terms: “fluoroquinolone,” “levofloxacin,” “complicated 
urinary tract infection,” “complicated UTI,” “cystitis,” 
“pyelonephritis,” “urinary tract infection,” and “UTI.” This 
query was also limited to English-language publications. 
The search criteria were chosen to maximize the sensitivity 
of the search. The same search criteria were used to query 
the Cochrane Database of Clinical Trials and the Clinical 
Trials.gov database. We included all English-language pub-
lications of either randomized controlled trials or analytical 
observational studies of the efﬁ  cacy of levoﬂ  oxacin in treat-
ing cUTI and/or AP that were published before February 1, 
2008. We excluded studies performed in pediatric patients 
or that included no comparator group. For each publication, 
the authors’ deﬁ  nition of cUTI and AP were used. The cita-
tions of all included publications were also considered for 
inclusion in this review. All publications were assessed for 
potential duplication of reported data.
For each of the included publications, two authors 
extracted data on the study design and methods, the deﬁ  ni-
tions of key variables (cUTI, AP, microbiologic eradication, 
and clinical cure), timing of outcome assessments, efﬁ  cacy 
and safety results, infecting pathogens, and the presence 
and/or development of antibiotic resistance. Data extraction 
was conducted in this manner so as to evaluate not only the 
safety and efﬁ  cacy but also the generalizability of the studies 
to general practice.
Results
Study selection
The PubMed query yielded 385 publications. Of these, 
ﬁ  ve publications met the inclusion and exclusion criteria. 
However, one of these publications reported the ﬁ  ndings 
of a subset of patients (those with AP) and these data were 
also subsequently published with the results of the full trial 
(Klausner et al 2007; Peterson et al 2008). Thus, only the 
latter publication was included in this review (Peterson 
et al 2008). Of the publications that were excluded, 86% 
were excluded because they were not human subjects-based 
research (including, for example, systematic reviews), did not 
include levoﬂ  oxacin as a study drug, or were not evaluating 
therapies for cUTI or AP.
The query of the Cochrane Database of Clinical Trials 
yielded 55 publications. Of these, eight studies were not 
included because levoﬂ  oxacin was not evaluated, seven 
were excluded because they were not studies of cUTI or 
AP, 13 were non-English publications, and the remaining 
27 studies had already been identiﬁ  ed for consideration in 
the PubMed query. Similarly, the ClinicalTrials.gov query Therapeutics and Clinical Risk Management 2008:4(5) 846
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yielded 60 registered trials (some on-going). Of these trials, 
47 were not studies of cUTI or AP, four were conducted in 
pediatric patients, ﬁ  ve were studies not including levoﬂ  oxacin, 
and one was an uncontrolled study. Only three trials were 
identiﬁ  ed as having met inclusion and exclusion criteria. The 
ﬁ  ndings of these trials were published, either in whole or in 
part, in the publications identiﬁ  ed through PubMed. Thus, 
the summary data available through ClinicalTrials.gov were 
not included in this review. Review of the cited publications 
yielded one additional, previously unidentiﬁ  ed publication 
that met inclusion and exclusion criteria.
Five publications met all inclusion and exclusion criteria 
and are included in this review (Klimberg et al 1998; Richard 
et al 1998a, b; Peng 1999; Peterson et al 2008). Table 1 
summarizes the design of the trials reported in these publica-
tions. All ﬁ  ve publications reported the ﬁ  ndings of random-
ized controlled trials. One reported the results of two such 
trials (Richard et al 1998b); thus six trials were described 
among the ﬁ  ve publications. We should also note that three 
of the publications included in this review arise from two 
trials. More speciﬁ  cally, data from two trials for the subset 
of AP patients were published in one publication (Richard 
et al 1998b) and the data pertaining to the cUTI patients from 
each of these trials were published separately (Klimberg et al 
1998; Richard et al 1998a). From this point forward, we will 
consider these three publications as presenting the results of 
four distinct trials.
Overview of study designs
Three trials were conducted in the US (Klimberg et al 1998; 
Richard et al 1998b; Peterson et al 2008), two trials in the 
US and Canada (Richard et al 1998b), and one trial was 
conducted in Taiwan (Peng 1999). The latter was also the 
only single-center trial. Only two publications speciﬁ  cally 
stated that the targeted sample size was selected to show 
equivalence within a margin of 15% (Richard et al 1998a; 
Peterson et al 2008). One of these publications did not 
achieve the sample size targeted by their power calculation 
(Richard et al 1998a). The remaining trials, which were all 
of smaller sample sizes, did not speciﬁ  cally describe the 
statistical power, sample size, or margin of equivalence that 
the trial was designed to target.
The deﬁ  nition of cUTI varied across the four trials includ-
ing these patients. The trials performed by Peng and Peterson 
et al stated only that a diagnosis of cUTI was required, 
although females in the latter trial were also required to 
have at least one of the following complicating factors: 
neurogenic bladder or urinary retention; partial obstruction, 
renal tumor or ﬁ  brosis, distorted urethral structure; and/or 
intermittent catheterization (Peng 1999; Peterson et al 2008). 
The studies of cUTI published by Klimberg et al and Richard 
et al required that all subjects possess an anatomic or func-
tional abnormality of the urinary tract and at least one of the 
following symptoms: urgency frequency, dysuria, hematuria, 
or fever or history of fever (Klimberg et al 1998; Richard 
et al 1998a). Klimberg et al also required that patients present 
with a baseline urinary sample with more than ﬁ  ve urinary 
white blood cells/high-power ﬁ  eld (Klimberg et al 1998). 
Three trials also required that study participants present with 
105 or more colony-forming units (cfu)/mL of at least one 
species of uropathogen (Klimberg et al 1998; Richard et al 
1998a; Peterson et al 2008), although Peterson et al excluded 
patients with more than two species of uropathogen present 
at baseline (Peterson et al 2008).
Four trials included AP patients. In three of the trials, 
the deﬁ  nitions of AP were similar and required that patients 
present with 105 or more cfu/mL of at least one species of 
uropathogen and two or more of the following symptoms: 
fever, ﬂ  ank pain or costovertebral angle tenderness, periph-
eral white blood cell count (WBC) more than 12,500/mm3 or 
10% or greater bands, and/or WBC casts in the urine, or, in 
the case of Peterson et al a positive antibody-coated bacteria 
test (Richard et al 2002; Peterson et al 2008). Similar to the 
deﬁ  nition of cUTI, Peterson et al required that subjects with 
AP have at least one of the following symptoms: urgency 
frequency, dysuria, hematuria, or fever or history of fever 
(Peterson et al 2008). In contrast, Peng required only a 
diagnosis of AP (Peng 1999). All trials assessed the outcomes 
of microbiologic eradication and clinical success. These 
deﬁ  nitions were similar across all trials (Table 1).
In each of the six trials, another ﬂ  uoroquinolone was 
selected as the comparator treatment (ciproﬂ  oxacin in three 
trials, lomeﬂ  oxacin in two trials, and oﬂ  oxacin in one trial). 
One trial allowed patients to be administered either oral or 
intravenous formulations. The efﬁ  cacy and safety results 
of this trial were not stratiﬁ  ed by formulation, although 
97% of the intention to treat group were started on an oral 
formulation of either levoﬂ  oxacin or the comparator (Peter-
son et al 2008). The ﬁ  ve remaining trials evaluated oral 
administration of levoﬂ  oxacin. Of these, four trials were 
speciﬁ  cally limited to outpatients and/or patients deemed 
appropriate candidates for oral therapy (Klimberg et al 1998; 
Richard et al 1998a, b). Five trials speciﬁ  cally included 
in their deﬁ  nitions of cUTI and AP that patients’ urine 
cultures at the time of enrollment must contain at least 105 
cfu/mL of a uropathogen (Klimberg et al 1998; Richard et al Therapeutics and Clinical Risk Management 2008:4(5) 847
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spp., and Enterococcus spp. While not all studies reported 
the frequency with which these organisms were isolated, 
among those that did, K. pneumoniae was isolated on average 
in 16% of subjects, while the remaining uropathogens were 
all isolated in 10% or less of subjects. Among the studies 
that reported species-speciﬁ  c microbiologic eradication 
rates, eradication failed on average in 7% of cases caused by 
E. coli within levoﬂ  oxacin-treated subjects (Klimberg et al 
1998; Richard et al 1998a; Peterson et al 2008). Peterson 
et al reported that levoﬂ  oxacin non-susceptible bacteria 
were isolated from 6% of levoﬂ  oxacin-treated subjects, and 
that no acquired resistance was observed (Peterson et al 
2008). In their cUTI trial, Richard et al (1998a) reported that 
9.8% of isolates tested were not susceptible to levoﬂ  oxacin 
(Richard et al 1998a). These were the only publications to 
provide these data.
As may be expected, the usage of urinary catheters was 
observed in a number of patients in the included trials. All 
of the included studies allowed the inclusion of catheter-
ized patients, but only 2 of the studies reported the total 
number of these patients, which constituted approximately 
5% of the subjects enrolled in these trials (Klimberg et al 
1998; Peterson et al 2008). Only one of the trials reported 
outcomes based on catheter usage. Peterson et al reported 
a signiﬁ  cantly worse microbiologic eradication in the 68 
catheterized patients compared to those without catheters 
(74.1% vs 89.0%; 95% CI: −26.6% to −3.3%).
Clinical response
Clinical success was observed to range from 82.6% to 93% 
when measured after the completion of therapy (Table 2). 
Again, Peng (1999) measured clinical efﬁ  cacy mid-treatment 
and observed a clinical success rate of 90%. Statistical testing 
of the differences in clinical efﬁ  cacy was only reported in 
three publications, and none of these reported any signiﬁ  cant 
difference between the levoﬂ  oxacin and comparator groups 
(Richard et al 1998a; Peng 1999; Peterson et al 2008). In 
the remaining two publications, reported clinical efﬁ  cacy 
rates were higher for levoﬂ  oxacin than for the comparator 
(Klimberg et al 1998; Richard et al 1998b).
Adverse events
Only Peterson et al (2008) reported the occurrence of serious 
adverse events (17 events in levoﬂ  oxacin-treated study 
subjects). While not all events were detailed in the publication, 
one allergic reaction and one death were reported. The 
death was not found to be treatment-related. Adverse event 
rates were similar for levoﬂ  oxacin and comparators in all 
1998a, b; Peterson et al 2008). Four of these trials excluded 
subjects with previous infections with organisms known to 
be resistant to any study medication (Klimberg et al 1998; 
Richard et al 1998a, b). The ﬁ  fth excluded subjects if the UTI 
was caused by a pathogen resistant to either study medication 
(Peterson et al 2008).
Four trials also excluded patients with decreased renal 
function. Peng excluded patients with renal failure (and other 
extremely severe underlying diseases) (Peng 1999). Of the 
two trials described in Richard et al, one excluded all patients 
with a creatinine clearance less than 50 mL/min and the 
second excluded those with a creatinine clearance less than 
20 mL/min (Richard et al 1998b). In the latter trial, dosing 
was altered for those with a creatinine clearance between 
20 and 50 mL/min. This same exclusion criteria (creatinine 
clearance of less than 20 mL/min) and altered dosing scheme 
was also applied in the study by Klimberg et al (Klimberg 
et al 1998). In both publications, no data were provided as 
to the number of patients receiving altered dosing, nor were 
the efﬁ  cacy and safety results reported within this subset of 
subjects. Richard et al’s cUTI trial also excluded patients 
with creatinine clearance less than 50 mL/min (Richard 
et al 1998a).
Microbiologic response
Microbiologic eradication rates for levofloxacin were 
high in all trials. When assessed after the completion of 
therapy, eradication rates ranging from 79.8% to 95.3% 
were observed (Table 2). These rates were not statistically 
signiﬁ  cantly different from that of the comparator treatments. 
Peng evaluated microbiologic efﬁ  cacy only on day 5 of a 
10-day course of levoﬂ  oxacin and observed an eradication 
rate of   90%, which was also not signiﬁ  cantly different 
from that of the comparator (Peng 1999). Richard et al 
reported relapse rates from the two trials described in that 
publication; at 4–6 weeks post-therapy, microbiologic relapse 
was observed in 13% of levoﬂ  oxacin-treated subjects and in 
6.5% of comparator-treated (ciproﬂ  oxacin or lomeﬂ  oxacin) 
study subjects. The difference was not statistically signiﬁ  -
cant (Richard et al 1998b). In their cUTI trial, Richard et al 
(1998a) reported a relapse rates of 9% in the levoﬂ  oxacin-
treated group at 4–6 weeks post-therapy, though 38% of the 
relapse cases were asymptomatic.
All publications provided information regarding the 
uropathogens that were most frequently isolated, and in all 
E. coli was the most commonly isolated (average = 61%). 
Other commonly isolated pathogens included K. pneumoniae, 
Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter Therapeutics and Clinical Risk Management 2008:4(5) 849
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publications. Only one publication speciﬁ  cally reported that 
no statistically signiﬁ  cant differences in individual adverse 
event rates were found between treatment groups (Peterson 
et al 2008). The most commonly observed adverse events 
across all of the trials include: headache, diarrhea, dyspepsia, 
nausea, dyspnea, vaginitis, ﬂ  atulence, and dizziness. Labora-
tory test abnormalities were infrequently reported. Klimberg 
et al (1998) reported that changes in clinical laboratory results 
occurred infrequently and were comparable across groups. 
Peng (1999) described patients receiving levoﬂ  oxacin who 
experienced elevated alanine aminotransferase, potassium, 
blood urea nitrogen, and hemoglobin, but these laboratory 
changes were not attributed to levoﬂ  oxacin therapy. No other 
studies described laboratory value alterations.
Acute pyelonephritis versus
complicated UTI
Four of the trials included in this review included patients 
with cUTI. However, two of these trials included patients 
with AP, and did not provide results stratiﬁ  ed by infection. Of 
these two studies, that of Peng (1999) consisted primarily of 
AP patients (16/20 in the levoﬂ  oxacin arm and 19/26 in the 
oﬂ  oxacin arm), while Peterson et al (2008) enrolled primarily 
cUTI patients (391/537 in the levoﬂ  oxacin arm and 391/556 
in the ciproﬂ  oxacin arm). The average levoﬂ  oxacin efﬁ  cacy 
rates for the two publications reporting efﬁ  cacy for cUTI 
alone was 93.5% for microbiologic eradication and 92.6% for 
clinical success (Klimberg et al 1998; Richard et al 1998a). 
While Peterson et al did not report stratiﬁ  ed efﬁ  cacy results, 
a second publication by the authors (that was not included 
in this review due to duplicity) reports the results for AP 
patients alone. This publication also found levoﬂ  oxacin to 
be equivalent to the comparator (ciproﬂ  oxacin) in both safety 
and efﬁ  cacy (Klausner et al 2007). The average levoﬂ  oxacin 
efﬁ  cacy rates for this publication and Richard et al’s report of 
two AP trials were 88.3% for microbiologic eradication and 
88.5% for clinical success. Also noteworthy is that Peterson 
et al (2008) is the only trial of high-dose, short duration 
levoﬂ  oxacin therapy. This trial observed efﬁ  cacy rates that 
were 12.8% lower on average for microbiologic eradication 
and 9.2% lower on average for clinical success than reported 
by the other publications. As described above, this was also 
the only trial to report the occurrence of serious adverse 
events among levoﬂ  oxacin-treated study subjects.
Discussion
The objective of this review was to provide a summary of 
the existing efﬁ  cacy and safety data pertaining to the use 
of levoﬂ  oxacin for the treatment of cUTI and AP. While 
our search of the literature revealed only ﬁ  ve publications 
meeting the criteria for inclusion, all reported generally 
high microbiologic and clinical efﬁ  cacy rates with minimal 
occurrences of serious adverse events. Despite this, the 
paucity of data in this area leaves several questions as to the 
generalizability of these trials.
The US FDA approves medications for the indication of 
urinary tract infections, including pyelonephritis, under two 
categories: (1) uncomplicated urinary tract infections and 
(2) complicated urinary tract infections and pyelonephritis. 
The trials included in this review used deﬁ  nitions generally 
consistent with this classiﬁ  cation. In contrast to this, the 
IDSA has utilized a relatively more complex categorization 
scheme that recommends the use of the following categories 
in the evaluation of   anti-infectives for urinary tract 
Table 2 Summary of reported microbiologic and clinical efﬁ  cacy data
Condition Efﬁ  cacy after completion 
of therapy
No. subjects 
evaluated
Days post-therapy Signiﬁ  cantly 
different from 
comparator(s)?a
Microbiologic Clinical
Klimberg et al 1998c cUTI 95.3% 93.0% 171 5–9 Nof
Peng 1999d AP and cUTI 90.0% 90.0% 20 −5 No
Peterson et al 2008b AP and cUTI 79.8% 82.6% 317 5–7 No
Richard et al 1998ac,e AP 94.0% 92.0% 89 5–9 Nog
Richard et al 1998b cUTI 91.0% 92.0% 126 5–9 No
aalpha = 0.05.
bData are presented from the modiﬁ  ed intention to treat analysis.
cData are presented from the microbiologically evaluable study subjects; efﬁ  cacy not reported for intention to treat or modiﬁ  ed intention to treat groups.
dNo end of therapy endpoint assessed. Data presented was collected on day 5 of therapy.
ePublication reports the ﬁ  ndings of two trials; average efﬁ  cacy presented here.
fStatistical comparison performed only for microbiologic efﬁ  cacy outcome.
gNo statistical comparisons reported; however, microbiologic and clinical efﬁ  cacy rates for levoﬂ  oxacin were higher than for the comparators.
Abbreviations: AP,  acute pyelonephritis; cUTI, complicated urinary tract infection.Therapeutics and Clinical Risk Management 2008:4(5) 850
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infections: (1) acute uncomplicated UTI in women, (2) acute 
uncomplicated pyelonephritis, (3) complicated UTI and UTI 
in men, (4) asymptomatic bacteriuria, and (5) recurrent UTI 
(antimicrobial prophylaxis) (Rubin et al 1992). While the 
FDA acknowledges that AP can be either an uncomplicated 
or complicated disease, it justiﬁ  es the aggregation of all AP 
with cUTI by noting that antibiotic dosing regimens for these 
conditions are generally similar (US Department of Health 
and Human Services et al 1998). Nevertheless, clinical 
and/or microbiologic responses may vary between patients 
with different complicating factors, including such factors 
as physical obstruction of the urinary tract, male gender, 
and immunosuppression. These differences may stem from 
the need for additional interventional therapies to ensure the 
resolution of the infection. For example, cUTI patients with 
anatomical abnormalities may require surgery, and for those 
with neurogenic bladders, catheterization may be necessary 
to manage urination (Matsumoto et al 2001; Neal 2008).
Studies of cUTI included in this review generally did not 
present efﬁ  cacy results stratiﬁ  ed according to the speciﬁ  c 
complicating factor(s). One exception is the trial performed 
by Peterson et al (2008), which reported signiﬁ  cantly differ-
ent microbiologic eradication rates among the catheterized 
and non-catheterized patients. These results suggest that the 
presence of catheters may inﬂ  uence outcomes in these studies, 
and stratiﬁ  cation of results by catheter usage is warranted. 
We agree with others who have recommended that studies 
including patients with cUTI should report results stratiﬁ  ed 
according to speciﬁ  c patient characteristics, since patients 
with cUTI present with a heterogeneous collection of factors 
that make their infection complicated (Naber 1999).
All of the clinical studies presented compared levoﬂ  oxacin 
with another ﬂ  uoroquinolone. All studies reported similar 
microbiologic and clinical responses for these comparators. 
No data are available regarding a comparison of levoﬂ  oxacin 
with other classes of antimicrobials. In general, this may 
be due to a lack of suitable oral alternatives. While direct 
comparisons are lacking, it has been noted that similar 
microbiologic success rates ranging from 71%–91% have 
been reported in trials using beta-lactams and monobactams 
(piperacillin/tazobactam, ceftriaxone, aztreonam, 
ceftazidime), carbapenems (imipenem, meropenem, 
ertapenem) and aminoglycosides (amikacin) (Melekos et al 
1991; Nowe 1994; Cox et al 1995; Wells et al 2004). It is 
not possible to directly compare the results of these studies 
to the included levoﬂ  oxacin studies, but crude efﬁ  cacy rates 
were similar. Additional research using non-ﬂ  uoroquinolone 
comparators would provide not only direct comparisons of 
efﬁ  cacy, but would also provide for direct comparisons in 
safety proﬁ  les, which may vary to a greater extent between 
antimicrobial classes.
Levoﬂ  oxacin was generally well-tolerated in all of the 
reviewed trials; this is consistent with what has been observed 
in other settings at the currently approved doses (Anderson 
and Perry 2008). A pooled analysis of patients with respi-
ratory tract infections who were prescribed levoﬂ  oxacin 
500 mg or 750 mg found that patients receiving both 
doses experienced a similar rate of adverse events during 
treatment, and the speciﬁ  c adverse events observed were 
similar to those in the trials reviewed here (Khashab et al 
2006). Additional adverse events not commonly reported 
in the reviewed publications, but that have been reported in 
association with levoﬂ  oxacin, include photosensitivity, QTc 
prolongation, hypersensitivity, convulsions, Clostridium 
difﬁ  cile-associated diarrhea, and tendon rupture; many of 
these adverse reactions are rarely reported and have been 
associated with other ﬂ  uoroquinolones (Anderson and Perry 
2008). A comprehensive review of adverse events associated 
with ﬂ  uoroquinolone use is not included here; the reader 
is referred to a recent review of this topic (Mehlhorn and 
Brown 2007).
Two of the trials that we reviewed included patients 
who received altered levoﬂ  oxacin doses based upon renal 
function, although results were not stratiﬁ  ed according to 
the dose received (Klimberg et al 1998; Richard et al 1998b). 
An inherent difference in clinical or microbiologic response 
would not be expected in these patient groups, assuming 
that dosing according to renal function was performed 
appropriately. However, further evidence of the efﬁ  cacy 
of the various approved dosing regimens of  levoﬂ  oxacin is 
needed. Similarly, the trial by Peterson et al (2008) did not 
report outcomes that were stratiﬁ  ed according to whether 
patients received oral or intravenous therapy. Based on 
levoﬂ  oxacin’s oral bioavailability of 100%, we do not expect 
that patients receiving oral levoﬂ  oxacin would experience 
poorer outcomes than those receiving intravenous therapy; 
however, receipt of intravenous therapy may be a marker of 
more severe illness (eg, bacteremic patients) and thus a more 
thorough analysis of efﬁ  cacy that is stratiﬁ  ed by the route of 
administration is warranted.
The majority of the patients included in the trials 
described in this review presented with infections of moderate 
severity, and most studies included only patients who 
received oral therapy on an outpatient basis. The clinical 
and microbiologic efﬁ  cacy of levoﬂ  oxacin in patients with 
more severe illness (including hospitalized patients) requires Therapeutics and Clinical Risk Management 2008:4(5) 851
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further study. Furthermore, larger studies are needed so that 
levoﬂ  oxacin’s efﬁ  cacy can be evaluated among patients 
infected with organisms other than E. coli, since the incidence 
of antimicrobial resistance in urinary tract infections caused 
by these pathogens is not well-described, and cUTI and 
AP are frequently caused by pathogens other than E. coli 
(Nicolle 1997).
Furthermore, few studies provided meaningful informa-
tion regarding the development of ﬂ  uoroquinolone resistance. 
Although ﬂ  uoroquinolone resistance in such uropathogens 
as E. coli remains somewhat rare in the US, the prevalence 
of such resistance is undoubtedly increasing. Regional 
variations in the prevalence of levoﬂ  oxacin resistance have 
already been identiﬁ  ed within the US, where the prevalence 
of resistance varies from 3.7% in New England to 9.1% in the 
Mid-South region (David et al 2005). Peterson et al (2008) 
was the only publication to report data on resistance that 
emerged during the course of therapy, though they reported 
zero occurrences of this event. Fluoroquinolone-resistant 
E. coli has also been isolated in the rectal ﬂ  ora of patients 
who received ciproﬂ  oxacin for acute uncomplicated cystitis; 
thus, evaluating resistance in urinary isolates alone may be 
insufﬁ  cient (Gupta et al 2005). With the recent proliferation 
of TMP/SMX-resistant E. coli, fluoroquinolones have 
frequently become the recommended empiric therapy of 
choice for acute uncomplicated cystitis (Le and Miller 2001; 
Warren 2001). In fact, a recent study found that ﬂ  uoroquino-
lones had replaced TMP/SMX nationwide as the preferred 
ﬁ  rst-line antimicrobial for uncomplicated cystitis (Kallen 
et al 2006). Unfortunately, the long-term viability of this 
strategy in the face of increasing ﬂ  uoroquinolone resistance 
is uncertain, and investigations of ﬂ  uoroquinolone-sparing 
regimens for cUTI and AP, using agents such as TMP/SMX, 
are needed (Kallen et al 2006; Gupta et al 2007). The future 
use of ﬂ  uoroquinolones in the management of cUTI and 
AP is also threatened by the ongoing increase in the num-
ber of these infections that are caused by ESBL-producing 
Enterobacteriaceae, which tend to display cross-resistance 
to ﬂ  uoroquinolones (Muratani and Matsumoto 2006; Baudry 
et al 2008). Furthermore, E. coli isolates may harbor resis-
tance-conferring mutations yet appear to be fully-susceptible 
according to susceptibility breakpoint standards established 
by the Clinical and Laboratory Standards Institute (Komp 
Lindgren et al 2003). New trials that examine levoﬂ  oxacin in 
the setting of cUTI and/or AP should include data regarding 
the prevalence of resistance (whether it is present in the 
original infecting isolate or develops during ﬂ  uoroquinolone 
therapy), as it is a mitigating factor in treatment failure, 
and ongoing surveillance of antimicrobial resistance in 
uropathogens is of paramount importance.
In the case of uncomplicated urinary tract infections, 
significant research has led to reduced durations of 
antimicrobial therapy in patients with these infections. 
Reducing unnecessarily long durations of therapy is one 
aim of the judicious antimicrobial movement, which aims 
to reduce the evolutionary selective pressures that drive the 
emergence and growing prevalence of antibiotic resistance. 
In 2007, the US FDA approved a higher dose, shorter duration 
levoﬂ  oxacin regimen for cUTI and AP. We identiﬁ  ed only 
one trial, sponsored by Ortho-McNeil Pharmaceuticals, Inc., 
in which this therapy was evaluated. Although both micro-
biologic and clinical efﬁ  cacy results were slightly lower for 
this regimen (750 mg daily for 5 days) than had been reported 
in other trials using longer durations of lower-dose therapy, 
this trade-off may be acceptable in patients with less severe 
disease and may help to limit the increasing development of 
ﬂ  uoroquinolone resistance.
Conclusions
Levoﬂ  oxacin has demonstrated high rates of microbiologic and 
clinical success, with outcomes similar to those obtained by 
comparator ﬂ  uoroquinolones in the included trials. All of the 
available ﬂ  uoroquinolones possess activity against common 
uropathogens, including E. coli, and most of these agents 
display favorable pharmacokinetics in the setting of UTI. 
Alternatives to the ﬂ  uoroquinolones for the treatment of cUTI 
and AP include penicillins, cephalosporins, and TMP/SMX; 
little data regarding the comparative efﬁ  cacy of these agents 
is available. It is difﬁ  cult to assess the generalizability of stud-
ies of cUTI and/or AP because of the lack of a standardized 
deﬁ  nition of cUTI, a high degree of variability in study design, 
and the level of stratiﬁ  cation with which data are reported. An 
important clinical outcome that was not adequately reported 
in the majority of these publications was the development of 
antimicrobial resistance while receiving therapy. This may 
be an important distinguishing factor among antimicrobials. 
Ongoing surveillance for ﬂ  uoroquinolone resistance among 
uropathogens is needed so that these data can be applied in the 
empiric therapy decision-making process. Furthermore, more 
research is needed to determine optimal treatment durations 
and dosing regimens for antibiotics in the treatment of cUTI 
and AP. Rational antibiotic use for high-incidence infections, 
such as the UTIs, are critical to the control of increasing anti-
biotic resistance (David et al 2005). Although levoﬂ  oxacin has 
been associated with favorable outcomes in patients with AP 
and cUTI, further comparative trials are needed to establish the Therapeutics and Clinical Risk Management 2008:4(5) 852
McGregor et al
role of levoﬂ  oxacin in comparison to alternative antimicrobial 
classes in the management of these infections.
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